Elite Pharmaceuticals, Inc. renewed its License, Supply, and Distribution Agreement with Lannett Company, Inc. to market two Elite generic products in the United States. Lannett will continue to be the exclusive U.S. distributor for the two generic products that Elite and Mikah Pharma co-own. This First Renewal Term shall be from March 22, 2022 until March 5, 2024.

The first product is a generic version of Adderall, an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg tablets. The second product is a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg tablets. Under the Agreement, Lannett will provide sales, marketing, and distribution for the products, and Elite will manufacture the product.

Lannett, Elite, and Mikah will each receive a share of the profits.